Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2016. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) under the Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding executive share awards rather than a financial performance report.
Material Changes
The filing details a change in the shareholding of Mrs. V. Whyte, a PDMR. On February 11, 2016, she acquired an interest in 11,800 Ordinary Shares of GlaxoSmithKline plc through awards made under the GlaxoSmithKline 2009 Performance Share Plan.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or outlook. The only risk or contingency noted is that the vesting of the awarded shares is subject to meeting performance criteria over a three-year period. The closing price of an Ordinary Share on the transaction date (February 11, 2016) was £13.45.
Investor Verification Points
- Verify the specific performance criteria required for the vesting of the 11,800 shares awarded to Mrs. V. Whyte.
- Confirm the total number of shares held by Mrs. V. Whyte post-transaction to assess total exposure.
- Review the GlaxoSmithKline 2009 Performance Share Plan terms for details on the three-year vesting schedule.